ÐÓ°ÉÂÛ̳

Diabetes Expenditure, Burden of Disease and Management in 5 EU Countries


January 2012

Diabetes expenditure, burden of disease and management in 5 EU Countries

Diabetes mellitus (DM) is associated with a high risk of developing complications and severe co-morbidities. Over the past few years, diabetes (Type 1 and 2)and its associated costs have risen, particularly those related to treatment of complications.

Our aims are to identify and compare the diabetes burden of disease, costs (direct and indirect) and diabetes outcomes, focusing on complications across France, Germany, Italy, Spain, and the UK (EU5). We will then have an understanding of the state of diabetes management in EU5 from which to make informed policy options.

A survey was designed and sent to health economists in the EU5 countries. In turn, key diabetes clinicians, decision makers and health officials wereinterviewed in order to answer the survey. In addition, secondary data was collected from PubMed, diabetes association publications and health government publications and websites, including national statistics.

 

Client: Novo Nordisk

Authors: Panos Kanavos, Stacey van den Aardweg & Willemien Schurer

Download report